Delivery Order SPE2DR25D1205-SPE2DR26F0XA7
- Not listed
- The Defense Logistics Agency awarded a $15,045.54 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on November 5, 2025, with completion expected by November 6, 2025. This non-competitive delivery order was issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The product will be delivered to AmerisourceBergen's corporate headquarters...
- The Defense Logistics Agency awarded a delivery order valued at $13,037.95 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on October 23, 2025, with completion scheduled for October 24, 2025. This non-competitive, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger indefinite delivery contract vehicle with DLA Troop Support Medical. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $12,446.64 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on September 8, 2025, with completion scheduled for September 9, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award to the pharmaceutical distributor's Corporate Office located in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a $3,111.66 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count) on July 14, 2025, with completion due July 15, 2025. This non-set-aside award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,847.74 to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count units). This firm fixed-price delivery order, with an ultimate completion date of July 22, 2025, represents a non-set-aside competitive award to support federal pharmaceutical procurement requirements. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $14,136.53 for RINVOQ ER 15 mg tablets (30-count units) on July 29, 2025, with an ultimate completion date of July 30, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order represents a single transaction under AmerisourceBergen's broader...
- The Defense Logistics Agency awarded a delivery order valued at $7,181.62 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) with a firm fixed price and September 23, 2025 completion date. This is a competitively awarded, non-set-aside contract for pharmaceutical supply to support federal medical procurement needs. The award was issued to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, the company's headquarters, which serves as a critical...
- The Defense Logistics Agency awarded a delivery order valued at $12,922.12 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) with a firm fixed-price structure. This contract was competitively awarded without set-aside designation and is set to complete by August 29, 2025. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a potential value of...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,931.68 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 4, 2025, with completion scheduled for August 5, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. The pharmaceutical distributor,...
- The Defense Logistics Agency awarded a $73,325.24 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 MG tablets (30-count units) with a completion date of June 2, 2025. This non-set-aside contract represents a competitive award to the pharmaceutical distributor's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999 prime...
- SPE2DR25D1205Indefinite Delivery Contract
- SPE2DR25D1205-SPE2DR26F0XA7Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $11,115.20 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on November 20, 2025, with an ultimate completion date of November 21, 2025. This firm fixed-price delivery order represents a non-competitive award and falls under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December 2026. The prime contract serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply pharmaceutical products and medical supplies to support military healthcare programs worldwide. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical federal vendor for military and veteran healthcare systems. The company's contract portfolio with the Defense Logistics Agency demonstrates extensive experience fulfilling federal medical procurement requirements across multiple therapeutic domains, including specialty medications, branded and generic pharmaceuticals, and medical devices. The company's demonstrated capability to meet federal procurement standards through competitive award processes, combined with its substantial IDC with DLA, positions it as a key supplier for the Department of Defense's pharmaceutical needs across global operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.1k | 11/20/25 |